Preparation and evaluation of transnasal microemulsion of carbamazepine  by Acharya, Sheetal Porecha et al.
ww.sciencedirect.com
a s i a n j o u rn a l o f p h a rma c e u t i c a l s c i e n c e s 8 ( 2 0 1 3 ) 6 4e7 0Available online at wScienceDirect
journal homepage: ht tp: / /ees.elsevier .com/ajps/defaul t .aspOriginal Research Paper
Preparation and evaluation of transnasal microemulsion
of carbamazepineSheetal Porecha Acharya a,*, K. Pundarikakshudu a, Aashish Panchal a, Anita Lalwani b
a L. J. Institute of Pharmacy and Research Centre, Ahmedabad, Gujarat 382210, India
bKadi Sarva Vishwavidyalaya, Sector 15/23, Gandhinagar, Gujarat, Indiaa r t i c l e i n f o
Article history:
Received 2 January 2013
Received in revised form
4 February 2013
Accepted 17 February 2013
Keywords:
Carbamazepine
Epilepsy
Intranasal
Microemulsion* Corresponding author. Tel.: þ91 9427844662;
E-mail address: sheetaltarak@gmail.com (S.P
Peer review under responsibility of Shenyan
Production and hosting by El
1818-0876/$ e see front matter ª 2013 Sheny
http://dx.doi.org/10.1016/j.ajps.2013.07.008a b s t r a c t
The objective of this study was to develop novel transanasl microemulsion containing carba-
mazepine for treatmentof epilepsy.Oleic acidwas selectedasoilwhileTween80andpropylene
glycol were selected as surfactant and cosurfactant respectively based on solubility results.
Optimized ratio of Tween 80: propylene glycol was selected after developing pseudoternary
phase diagrams for different ratio and microemulsions were prepared. The prepared micro-
emulsions were evaluated for globule size, viscosity, pH, conductivity and% transmittance. Ex-
vivo diffusion study for optimizedmicroemulsion was performed through sheep nasal mucosa
wherein diffusion flux and permeability coefficients were determined. Further pharmacody-
namic performance was evaluated in rats by electrically induced seizures. It was found that
optimizedmicroemulsion was stable and transparent with average globule size of 190 nm and
diffusion flux of 75.77 mg cm2 min1 and showed no toxicity during histopathological evalu-
ation on sheep nasal mucosa. Pharmacodynamic evaluation also indicated lesser intensity of
seizures in rats treated with optimized formulation in comparison to rats treated with oral
carbamazepine microemulsion and nasal carbamazepine solution which suggested carba-
mazepine transnasal delivery systemasaneffective alternate therapy for treatmentof epilepsy.
ª 2013 Shenyang Pharmaceutical University. Production and hosting by Elsevier B.V. All
rights reserved.1. Introduction in developing countries. Epilepsy is more likely to occur inStatus epilepsy is a serious neurological emergency charac-
terized by severe bouts of seizures. It requires rapid termina-
tion of seizure activity because if the episode of epilepsy
remains untreated, it may lead to a permanent damage to the
brain [1]. About 50 million people worldwide suffer from epi-
lepsy and nearly two out of every three new cases are reportedfax: þ91 79 26890512.
. Acharya).
g Pharmaceutical Univer
sevier
ang Pharmaceutical Univyoung children or people over the age of 65 years however it
may occur at any age.
Treatments of epilepsy include treatment with antiepi-
leptic drugs or surgery. Carbamazepine (CBZ) is a major anti-
epileptic drug for the treatment of different form of seizures
[2]. Currently CBZ is available only in the form of oral dosage
forms including tablets, capsules, suspensions etc. The majorsity
ersity. Production and hosting by Elsevier B.V. All rights reserved.
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absorption and thus a novel formulation of carbamazepine to
overcome the stated limitation is mandatory [3].
In recent years, systemic drug delivery through nasal route
has received a lot of attention, because of its advantages
including rapid absorption, avoidance of hepatic first-pass
metabolism and the ability for preferential drug delivery to
brain via the olfactory region [4,5]. In comparison with oral
administration, intranasal drug delivery may provide an
improvement in bioavailability and rapid onset of action [6].
Thus, it is expected that intranasal delivery of CBZ may also
achieve rapid onset of action and improved bioavailability by
avoiding the first-pass effect in the liver and intestine. CBZ
transnasal formulations are not available in market. Some
researchers have worked on CBZ nasal formulations but
thorough characterization with pharmacodynamic studies
has not been reported by the researchers as per the authors’
knowledge [7].
CBZ aqueous solubility is very poor. Hence solubility
enhancement is necessary for intranasal delivery of CBZ as
nasal delivery cannot permit administration of large volumes
of liquids. Microemulsion (ME) seems to be convincing
approach for administration of CBZ. ME is defined as a ther-
modynamically stable and transient dispersion consisting of
oil, surfactant, cosurfactant and aqueous phases [8]. The ad-
vantages of ME as a drug delivery system are the enhance-
ment of drug solubilization and absorption across mucosal
membranes due to its lipophilic nature and smaller globule
size [9].
The objective of this investigation was to prepare and
optimize transnasal CBZ microemulsion by using various
physicochemical parameters including globule size, % trans-
mittance, pH, viscosity, etc. Optimized ME was further eval-
uated for ex-vivo diffusion study through sheep nasal mucosa.
Pharmacodynamic activity of CBZ ME was evaluated in rats
after inducing seizures electrically.2. Materials and methods
2.1. Materials
Carbamazepinewas donated by Lincoln Pharma, Ahmedabad,
India. Capmul MCM (glyceryl monocaprylate) and Labrafac
(propylene glycol dicaprylocaprate) were obtained as gift
samples from Gattefosse. Oleic acid, Tween 80, Tween 20,
Span 80, polyethylene glycol (PEG 400) and propylene glycol
(PG) were purchased from Sigma Aldrich. All other chemicals
were of analytical grade and purchased commercially. Double
distilled water was used throughout the study.
2.2. Determination of solubility of drug
The solubility of CBZ in various components (oils, surfactants,
and cosurfactants) was determined by adding an excess of
(1 g) CBZ to each cap vial containing 5 ml of the selected ve-
hicles. The mixture was heated at 40 C in a water bath to
facilitate the solubilization. Formed suspensions were then
stirred for 48 h onmagnetic stirrer. Then each suspensionwas
centrifuged at 3000 rpm for 5 min, and supernatant was takenand diluted with methanol and CBZ was quantified by UV
spectrophotometer (UV 1800, Shimadzu) at wavelength of
284 nm.
2.3. Preparation of pseudoternary phase diagram
Pseudoternary phase diagramswere constructed to obtain the
appropriate ratio of surfactant: cosurfactant which can result
in to large existence of ME area. They were constructed using
water titration method. Surfactant (Tween 80) and cosurfac-
tant (propylene glycol) were mixed (Smix) in different weight
ratios (1:1, 2:1 and 1:2). Oil (oleic acid) and Smix (Tween 80 and
propylene glycol) were mixed thoroughly in different weight
ratios from 1:9 to 9:1 in different glass vials and diluted with
distilled water in a drop wise manner till it changed from
transparent to opaque. By joining the change points, the
boundaries of phases formed were obtained in the phase di-
agrams. All samples exhibiting a transparent and homoge-
neous state were assigned to an ME region, a monophasic
area, in the phase diagram [10]. The pseudoternary phase di-
agrams were constructed by using CHEMIX software.
2.4. Physicochemical characterization of carbamazepine
loaded MEs
Percentage transmittance of each sample was determined at
630 nm using distilled water as reference. One drop of MEs
was placed on slide and refractive indices of MEs were
measured by using Abbe refractometer (ELICO, India).
Isotropic nature of MEswas verified by placing a drop of ME on
slide with cover slip on it and observing it under polarized
light using polarizing microscope (Carl Zeiss, Germany). Vis-
cosity of the MEs was measured by a Brookfield viscometer at
room temperature by using LV III spindle. Electrical conduc-
tivity of ME wasmeasured using a conductivity meter (CM 180
ELICO, India) at ambient temperature and the pH of ME was
measured by using pH meter (Systronic 335, India). Droplet
size and Zeta potential distribution was measured using
Malvern zetasizer (Nano ZS, Malvern Instruments, UK). Each
sample was suitably diluted five times with filtered distilled
water and placed in a disposable zeta cell [11]. Samples were
centrifuged at 3000 rpm for 15 min to determine centrifuga-
tion stability. Experiments were performed in triplicate for
each sample.
2.5. Ex-vivo diffusion studies
The use of natural membranes is very important for predict-
ing the potential drug release characteristic. Freshly excised
sheep nasal mucosa was obtained from slaughter house and
dipped immediately in phosphate buffer (pH 6.4). Cartilages
were removed properly and the mucosal membrane was iso-
lated and washed with phosphate buffer (pH 6.4). Ex-vivo drug
diffusion study was performed using a Franz-type diffusion
cell with a diameter of 10 mm and mucosa thickness of
0.20 mm. The tissue was stabilized in phosphate buffer (pH
6.4). The receptor compartment was filledwith 10ml diffusion
media (phosphate buffer pH 6.4 þ 30% PEG 400) to maintain
perfect sink condition while 2 ml ME (30 mg/ml) was placed in
donor compartment. Continuous slow stirring was
Table 1 e Solubility of CBZ in various excipients.
Material Solubility (mg/ml)
Sunflower oil 9.55  0.25
Soybean oil 16.22  0.97
Labrafac 5.46  0.20
Capmul MCM 10.11  0.47
Oleic acid 32.08  2.54
Tween 80 29.05  1.13
Propylene glycol 54.18  1.76
Alcohol 51.55  1.79
All values are expressed as mean of three readings.
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sion of pure drug was conducted by placing 2 ml of drug so-
lution in PEG 400 (30 mg/ml). Samples from the receptor
compartment were withdrawn at periodic time intervals,
filtered through 0.45 mm nylon filter paper and analyzed using
a UVeVisible spectrophotometer at 284 nm. Each removed
sample was replaced by an equal volume of diffusion me-
dium. The cumulative amount of CBZ permeated through the
skin was determined by the following equation [12]:
Qn ¼ Cn  Vo þ
Pn1
i¼1 Ci  Vi
S
Where Cn is the CBZ concentration of receptor medium after
each sampling time, Ci is the CBZ concentration for i sample,
Vo and V are the volumes of the receiver solution and sample,
respectively, and S is the effective diffusion area. The steady
state flux (Jss) was calculated from the slope of the steady state
portion of the line in the plot of drug amount permeated Vs
time (min) [13]. Permeability coefficient (Kp) was calculated by
dividing the flux with concentration of the drug in ME.
2.6. Nasal ciliotoxicity studies
Themethod described by Sheetal et al. was used for this study;
pieces of freshly excised sheep nasal mucosa with a thickness
of 0.2 mm were exposed to CBZ ME for 2 h followed by thor-
ough rinsing with PBS pH 6.4. In two other different sets of
experiments isopropyl alcohol (a strong mucociliary toxin)
and PBS pH 6.4 were used instead of CBZ ME for arriving at a
comparative analysis of the extent of damage caused by the
preparation. These pieces of mucosa were fixed in paraffin
blocks and fine sectionswere taken that were stained by eosin
and hematoxylin. The prepared slides were examinedwith an
optical microscope (Olympus, Model BX10, Japan) and photo-
micrographs (magnification 400) were taken. Similar proce-
dure was used in our previous study [14].
2.7. Pharmacodynamic studies
Maximal Electroshock:Sprague Dawley rats weighing between
200 and 250 g and exhibiting clear hind limb extension phase
during electrically induced convulsions were included in the
present study. The experimental protocol was approved by
the Institutional Animal Ethics.
Committee (No. LJIP/IAEC/09/2011e2012). Rats were divided
into 5 groups (n ¼ 6). The first and second groups were treated
intranasally with CBZ solution (60% PEG 400) and CBZ ME
respectively containing CBZ equivalent to 8.18 mg/kg body
weight (using a micropipette attached with low-density poly-
ethylene (LDPE) tubing, having 0.1 mm internal diameter at the
delivery site). In the third group CBZ solution containing CBZ
equivalent to 8.18 mg/kg body weight was administered
intraperitoneally (IP) while fourth group was treated with oral
CBZ ME containing CBZ equivalent to 8.18 mg/kg body weight.
The fifth group, not subjected to any treatment, served as
control. Electroconvulsions were produced by applying current
(150 mA, 0.2 s) through ear clip electrodes using electro-
convulsiometer (INCO, Ambala, India) after 60 min of admin-
istration of formulations and different phases of seizures were
measured. Briefly after application of current an immediatesevere tonic phase (E phase) was observed which was charac-
terized bymaximal extension of the anterior and posterior legs.
At the end of tonic phase clonic phase starts which was char-
acterized by paddling movement of the hind limb and shaking
of body. During stupor phase which was observed after tonic
and clonic phase rat remained silent without any movement.
Recovery timewas recorded as total time from starting of tonic
phase till animal regains its normal movement [15].3. Results and discussion
3.1. Solubility of drug
The saturated solubility of CBZ in various oils was reported in
Table 1. It is important that the nasal formulation have the least
volume. It can be done if the components of the ME that are
chosen have highest solubility for the drug. This was analyzed
using one variable at a time (OVAT) type of optimization. The
solubility of the drugwas determined in each component of ME
sequentially (oil, surfactant and then cosurfactant). Highest
solubility was observed in oleic acid. Thus oleic acid was
selected as oil for preparation of ME. Among the surfactants
studied, Tween 80 showed the highest solubility for carbamaz-
epine and previous studies have reported improved nasal ab-
sorption when Tween 80 was used as one of the ingredient [16].
Thus, Tween 80, surfactant with HLB 14, was selected as a sur-
factant and depending on the solubility results PG was selected
as cosurfactant, which also acts as permeation enhancer [16].
3.2. The pseudoternary phase diagrams
The components that showed maximum solubility were
further optimized using pseudoternary phase diagram as
shown in Fig. 1. The zone of ME was obtained. Six formula-
tions were then taken from each corner at random and the
best formulation was characterized thoroughly. It was found
that increasing concentration of Tween 80 incorporation of
water can be increased but solubility of drug decreases while
by increasing concentration of PG drug solubility increase but
incorporation of water decreases and highest ME area was
obtainedwith ratio of 1:1 and thus selected for further studies.
According to the ME area in the phase diagram, the carba-
mazepine loaded ME formulations were prepared as per the
composition shown in Table 2. ME systems were obtained by
mixing oil, surfactant and cosurfactant together and adding
Fig. 1 e Pseudoternary phase diagram using oleic acid as oil, Tween 80 as surfactant, propylene glycol as cosurfactant and
water (Tween 80: propylene glycol [ 2:1, 1: 1 and 1:2).
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water drop by drop to these oily phases withmagnetic stirring
at ambient temperature. The final concentration of CBZ in ME
systems was 30 mg/ml.3.3. Physicochemical characterization of carbamazepine
loaded MEs
The microemulsions for nasal administration are expected to
show higher permeation rate with minimum globule size.
Prepared microemulsions are expected to have good physical
stability with respect to phase separation and/or flocculation.Table 2 e Composition of selected ME.
S1 S2 S3 S4 S5 S6
Carbamazepine (g) 3 3 3 3 3 3
Oleic acid (%) 10 10 10 15 15 15
Tween 80 (%) 32.5 35 37.5 32.5 35 37.5
PG (%) 32.5 35 37.5 32.5 35 37.5
Water (%) 25 20 15 20 15 10This can be achieved when zeta potential values are negative
The pH values have to be close to nasal secretions (4.5e6.5)
and viscosity has to be moderate. pH and viscosity are
important factors affecting mucociliary action which if
affectedmay cause another set of complications. Additionally
the pH deviations may cause irritation to the patient [7].
Higher viscosity is preferred as it increases residence time but
permeation rate also decreases with increase in viscosity and
hence formulation should have moderate viscosity. Reported
values indicates viscosity in between 100 and 200 cps is suit-
able for nasal administration [16]. It also has been observed
the formulation containing water in external phase shows
less irritancy on nasal mucosa. Based on the above rationale
critical quality attributes and their desirable ranges were
defined as follows. i) External medium e water ii) globule size
e minimum iii) pH e 4.5e6.5 iv) viscosity e 100e200 cps. The
pH, viscosity, conductivity, globule size and zeta potential of
the prepared formulations are shown in Table 3. Result of
globule size indicated that smallest globule size was obtained
with formulation S3 with PDI 0.20, which is close to zero,
indicating that the prepared ME had uniform globule size and
thus it was selected for further studies as faster permeation is
expected when the globule size is small. The pH of the ME S3
Table 3 e Physicochemical parameters of ME.
S1 S2 S3 S4 S5 S6
% Assay 99.66  0.65 99.47  0.55 99.58  0.42 98.89  0.33 99.27  0.25 98.76  0.32
pH 5.31 5.29 5.45 5.69 5.27 5.67
Globule size (nm) 370  21 300  15 190  8 411  23 375  12 325  10
Conductivity (ms/cm) 0.25  0.04 0.25  0.03 0.24  0.02 0.24  0.04 0.23  0.04 0.22  0.05
Viscosity (cps) 190  5 195  3 193  2 177  5 189  2 200  5
% Transmittance 98.88 99.43 99.87 99.21 99.33 99.98
Zeta potential 0.2093 0.1895 0.1105 0.4929 0.1856 0.1756
All values are expressed as mean of three readings.
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chances of irritancy on nasal mucosa. The refractive index
was 1.44 and % transmittance was found to be greater than
99% which confirmed that prepared CBZ ME was transparent.
Isotropic nature of ME was also proved as ME appeared
completely dark under polarized microscope [17]. The con-
ductivity of the results confirmed the formation of solution
type of ME with water in continuous phase. Viscosity of the
optimized formulation was 193 cps which is suitable for nasal
administration. Zeta potential was negative which indicated
the stability of formulation as there were less chances of
globules aggregation. After centrifugation cycle it was found
that ME S3 was stable and no separation was observed which
indicated centrifugation stability. The optimized ME S3
remained clear and transparent even after 3 months of stor-
age. ME S3 was optimized from the prepared formulations as
per the attributes decided earlier in this section. Ex-vivo
permeation study and pharmacodynamic study was per-
formed by using optimized ME S3.3.4. Ex-vivo diffusion through sheep nasal mucosa
Ex-vivo diffusion study was performed by using sheep nasal
mucosa for optimized formulation S3 and CBZ solution pre-
pared in 60% PEG 400 and results were shown in Fig. 2). It was
found that cumulative amount of CBZ permeated through
sheep nasal mucosa was32744. 5 mg with a flux of0
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Fig. 2 e Ex-vivo CBZ diffusion through sheep nasal mucosa
from CBZ ME and CBZ solution.75.77 mg cm2min1 and permeability coefficient was found to
be 0.00253 cm2 min1from CBZ ME while in case of CBZ so-
lution cumulative amount of CBZ permeated through sheep
nasal mucosa was 24537.06 mg with a flux of 57.26 mg
cm2 min1 and permeability coefficient was found to be
0.00191 cm2 min1. The results clearly indicated faster
diffusion of CBZ from CBZ ME in comparison to CBZ solution.
The diffusion is faster due to presence of oleic acid, Tween 80
and PGwhich act as permeation enhancers. A biphasic release
profile was obtained in which initial faster release was due to
solubilized drug in continuous phase while slower rate was
due to CBZ release from the oil droplets. CBZ from ME per-
meates rapidly (more than 50% of drug in 90 min) through
nasal mucosa in comparison CBZ solution (less than 40% in
90 min).
3.5. Nasal ciliotoxicity studies
Results of nasal ciliotoxicity studies were shown in Fig. 3.
Nasal ciliotoxicity studies revealed that nasal mucosa treated
with PBS pH 6.4 (negative control) showed intact epithelium
layer without any necrosis while nasal mucosa treated with
isopropyl alcohol (positive control mucociliary toxic agent)
showed complete destruction of epithelium layer, necrosis
and even the deeper tissue parts were also destroyed. CBZ ME
prepared in our studies did not exhibit any toxicity as no
change could be noticed in the gross morphology and histol-
ogy of the nasal mucosa. Our results are on similar lines of the
observations reported by other workers on toxicity of oleic
acid and Tween 80 which are the major components of our
preparation [18].
3.6. Pharmacodynamic studies
The antiepileptic activity was assessed by observing the
extent of different stages of seizures including duration of
seizure, extension phase (E), clonus phase (F) and stupor
phase (S) and results were represented in Figs. 4 and 5. Sig-
nificant differences between the control and treated groups
were calculated using one way ANOVA followed by Tukey test
for exact comparison in pharmacodynamic study. Significant
reduction in E phase, clonus, stupor and duration of seizure
was observed in the rats treated with CBZ ME by intranasal
route and in comparison to group of rats treated CBZ solution
administered IN and CBZ ME administered intranasally
( p < 0.05, n ¼ 6). The results clearly indicated lesser intensity
Fig. 3 e Nasal ciliotoxicity study for CBZ ME. (A) Nasal mucosa treated with PBS pH 6.4. (B) Nasal mucosa treated with CBZ
ME. (C) Nasal mucosa treated with IPA.
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with intranasal CBZ ME.4. Conclusion
The carbamazepine loaded transnasal ME demonstrated
lesser intensity of seizures which may be due to larger extent
of selective nose to brain delivery of drug in comparison to
oral ME, oral solution and nasal solution of carbamazepine.
This may help in decreasing dose and frequency of admin-
istration of drug and may possibly maximize therapeutic
benefits and may also reduce cost of therapy. However
detailed animal study followed by thorough clinical trials is0
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Fig. 4 e Duration of seizure and E phase for different
treatments of carbamazepine where, *** indicate significant
difference in comparison to control, aaa indicate significant
difference in comparison to CBZ solution (IN), bbb indicates
significant difference in comparison to CBZ ME (oral).
Fig. 5 e Duration of clonus and stupor phase for different
treatments of carbamazepine where, *** indicate significant
difference in comparison to control, aaa indicate significant
difference in comparison to CBZ solution (IN), bbb indicates
significant difference in comparison to CBZ ME (oral).required to establish clinical safety and efficacy of this
formulation.
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